Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Features associated with survival in metastatic melanoma patients treated with patient-specific dendritic cell vaccines.

Dillman RO, Fogel GB, Cornforth AN, Selvan SR, Schiltz PM, DePriest C.

Cancer Biother Radiopharm. 2011 Aug;26(4):407-15. doi: 10.1089/cbr.2011.0973. Epub 2011 Aug 3.

PMID:
21812653
2.

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.

Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.

J Immunother. 2006 Sep-Oct;29(5):545-57.

PMID:
16971810
3.

Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.

Wei Y, Sticca RP, Holmes LM, Burgin KE, Li J, Williamson J, Evans L, Smith SJ, Stephenson JJ, Wagner TE.

Int J Oncol. 2006 Mar;28(3):585-93.

PMID:
16465362
4.

Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.

Dillman RO, Selvan SR, Schiltz PM, McClay EF, Barth NM, DePriest C, de Leon C, Mayorga C, Cornforth AN, Allen K.

Cancer Biother Radiopharm. 2009 Jun;24(3):311-9. doi: 10.1089/cbr.2008.0599.

PMID:
19538053
5.

Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.

Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, Gorin I, Robert C, Prince HM, Grob JJ, Leccia MT, Lesimple T, Wijdenes J, Bartholeyns J, Fridman WH, Salcedo M, Ferries E, Tartour E.

J Immunother. 2008 Jan;31(1):101-12.

PMID:
18157017
6.

Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival.

Cornforth AN, Fowler AW, Carbonell DJ, Dillman RO.

Cancer Immunol Immunother. 2011 Jan;60(1):123-31. doi: 10.1007/s00262-010-0925-y. Epub 2010 Oct 20.

PMID:
20960187
7.

Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.

Dillman RO, Cornforth AN, Depriest C, McClay EF, Amatruda TT, de Leon C, Ellis RE, Mayorga C, Carbonell D, Cubellis JM.

J Immunother. 2012 Oct;35(8):641-9.

PMID:
22996370
8.

Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.

Lesimple T, Neidhard EM, Vignard V, Lefeuvre C, Adamski H, Labarrière N, Carsin A, Monnier D, Collet B, Clapisson G, Birebent B, Philip I, Toujas L, Chokri M, Quillien V.

Clin Cancer Res. 2006 Dec 15;12(24):7380-8.

9.

Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome.

Ridolfi L, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Brolli C, Selva M, Scarpi E, Valmorri L, Nicoletti SV, Guidoboni M, Riccobon A, Ridolfi R.

Melanoma Res. 2011 Dec;21(6):524-9. doi: 10.1097/CMR.0b013e32834b58fa.

PMID:
21909041
10.

Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen.

Smithers M, O'Connell K, MacFadyen S, Chambers M, Greenwood K, Boyce A, Abdul-Jabbar I, Barker K, Grimmett K, Walpole E, Thomas R.

Cancer Immunol Immunother. 2003 Jan;52(1):41-52. Epub 2002 Nov 13.

PMID:
12536239
12.

Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells.

Schiltz PM, Dillman RO, Korse CM, Cubellis JM, Lee GJ, De Gast GC.

Cancer Biother Radiopharm. 2008 Apr;23(2):214-21. doi: 10.1089/cbr.2007.0432.

PMID:
18454690
13.

Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine.

O'Rourke MG, Johnson M, Lanagan C, See J, Yang J, Bell JR, Slater GJ, Kerr BM, Crowe B, Purdie DM, Elliott SL, Ellem KA, Schmidt CW.

Cancer Immunol Immunother. 2003 Jun;52(6):387-95. Epub 2003 Apr 8.

PMID:
12682787
14.

Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.

Salcedo M, Bercovici N, Taylor R, Vereecken P, Massicard S, Duriau D, Vernel-Pauillac F, Boyer A, Baron-Bodo V, Mallard E, Bartholeyns J, Goxe B, Latour N, Leroy S, Prigent D, Martiat P, Sales F, Laporte M, Bruyns C, Romet-Lemonne JL, Abastado JP, Lehmann F, Velu T.

Cancer Immunol Immunother. 2006 Jul;55(7):819-29. Epub 2005 Sep 27.

PMID:
16187085
15.

HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.

Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ.

Gynecol Oncol. 2006 Mar;100(3):469-78. Epub 2005 Oct 24.

PMID:
16249018
16.

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.

Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HM, Gerritsen MJ, Croockewit S, Coulie PG, Torensma R, Adema GJ, Figdor CG, de Vries IJ, Punt CJ.

Cancer Immunol Immunother. 2011 Feb;60(2):249-60. doi: 10.1007/s00262-010-0942-x. Epub 2010 Nov 11.

PMID:
21069321
17.

Dendritic cell gene therapy.

Onaitis M, Kalady MF, Pruitt S, Tyler DS.

Surg Oncol Clin N Am. 2002 Jul;11(3):645-60. Review.

PMID:
12487060
18.

DC therapy for metastatic melanoma.

Ingram SB, O'Rourke MG.

Cytotherapy. 2004;6(2):148-53. Review. No abstract available.

PMID:
15203991
19.

Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.

Haanen JB, Baars A, Gomez R, Weder P, Smits M, de Gruijl TD, von Blomberg BM, Bloemena E, Scheper RJ, van Ham SM, Pinedo HM, van den Eertwegh AJ.

Cancer Immunol Immunother. 2006 Apr;55(4):451-8. Epub 2005 Jul 21.

PMID:
16034562
20.

Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate.

Vilella R, Benítez D, Milà J, Lozano M, Vilana R, Pomes J, Tomas X, Costa J, Vilalta A, Malvehy J, Puig S, Mellado B, Martí R, Castel T.

Cancer Immunol Immunother. 2004 Jul;53(7):651-8. Epub 2004 Mar 16.

PMID:
14999431

Supplemental Content

Support Center